This company is no longer active
Resumen de acción CRXT.Q
Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
+ 2 riesgos adicionales
Competidores de Clarus Therapeutics Holdings, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0011 |
| 52 Week High | US$3.94 |
| 52 Week Low | US$0.001 |
| Beta | 0 |
| 1 Month Change | -92.81% |
| 3 Month Change | -94.63% |
| 1 Year Change | -99.92% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.99% |
Noticias y actualizaciones recientes
Rentabilidad de los accionistas
| CRXT.Q | US Pharmaceuticals | Mercado US | |
|---|---|---|---|
| 7D | 0% | 1.1% | 0.6% |
| 1Y | -99.9% | 9.4% | 23.9% |
Rentabilidad vs. Industria: CRXT.Q underperformed the US Pharmaceuticals industry which returned 6% over the past year.
Rentabilidad vs. Mercado: CRXT.Q underperformed the US Market which returned -10.9% over the past year.
Volatilidad de los precios
| CRXT.Q volatility | |
|---|---|
| CRXT.Q Average Weekly Movement | 47.7% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: CRXT.Q's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: CRXT.Q's weekly volatility has increased from 35% to 48% over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2003 | 16 | n/a | clarustherapeutics.com |
Resumen de fundamentos de Clarus Therapeutics Holdings, Inc.
| Estadísticas fundamentales de CRXT.Q | |
|---|---|
| Capitalización bursátil | US$57.22k |
| Beneficios(TTM) | -US$24.49m |
| Ingresos (TTM) | US$16.91m |
0.0x
Ratio precio-ventas (PS)0.0x
Ratio precio-beneficio (PE)¿Está CRXT.Q sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de CRXT.Q | |
|---|---|
| Ingresos | US$16.91m |
| Coste de los ingresos | US$3.62m |
| Beneficio bruto | US$13.29m |
| Otros gastos | US$37.77m |
| Beneficios | -US$24.49m |
Últimos beneficios comunicados
Jun 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.47 |
| Margen bruto | 78.58% |
| Margen de beneficio neto | -144.82% |
| Ratio deuda/patrimonio | -310.1% |
¿Cómo se ha desempeñado CRXT.Q a largo plazo?
Ver rendimiento histórico y comparativa